Trade BioCryst - BCRX CFD
Add to favourite- Summary
- Historical Data
| Spread | 0.07 | ||||||||
|
Long position overnight fee
Long position overnight funding adjustment
Go to platform | -0.024151% | ||||||||
|
Short position overnight fee
Short position overnight funding adjustment
Go to platform | 0.001929% | ||||||||
| Overnight fee time | 22:00 (UTC) | ||||||||
| Min traded quantity | 1 | ||||||||
| Currency | USD | ||||||||
| Margin | 5.00% | ||||||||
| Stock exchange | United States of America | ||||||||
| Commission on trade | 0% |
| Prev. Close | 7.42 |
| Open | 7.34 |
| 1-Year Change | 39.28% |
| Day's Range | 6.93 - 7.34 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
| Date | Close | Change | Change (%) | Open | High | Low |
|---|---|---|---|---|---|---|
| Nov 15, 2024 | 7.00 | -0.34 | -4.63% | 7.34 | 7.47 | 6.90 |
| Nov 14, 2024 | 7.42 | -0.22 | -2.88% | 7.64 | 7.71 | 7.37 |
| Nov 13, 2024 | 7.61 | -0.21 | -2.69% | 7.82 | 7.96 | 7.60 |
| Nov 12, 2024 | 7.79 | -0.32 | -3.95% | 8.11 | 8.21 | 7.75 |
| Nov 11, 2024 | 8.16 | 0.32 | 4.08% | 7.84 | 8.21 | 7.82 |
| Nov 8, 2024 | 7.75 | 0.27 | 3.61% | 7.48 | 7.80 | 7.48 |
| Nov 7, 2024 | 7.63 | 0.08 | 1.06% | 7.55 | 7.84 | 7.47 |
| Nov 6, 2024 | 7.69 | 0.55 | 7.70% | 7.14 | 7.70 | 7.07 |
| Nov 5, 2024 | 7.02 | -0.32 | -4.36% | 7.34 | 7.34 | 7.00 |
| Nov 4, 2024 | 7.31 | -0.37 | -4.82% | 7.68 | 7.68 | 6.81 |
| Nov 1, 2024 | 8.40 | 0.45 | 5.66% | 7.95 | 8.40 | 7.95 |
| Oct 31, 2024 | 7.98 | -0.34 | -4.09% | 8.32 | 8.35 | 7.96 |
| Oct 30, 2024 | 8.33 | 0.34 | 4.26% | 7.99 | 8.33 | 7.95 |
| Oct 29, 2024 | 8.08 | 0.02 | 0.25% | 8.06 | 8.14 | 7.97 |
| Oct 28, 2024 | 8.12 | 0.16 | 2.01% | 7.96 | 8.19 | 7.95 |
| Oct 25, 2024 | 7.92 | -0.24 | -2.94% | 8.16 | 8.19 | 7.92 |
| Oct 24, 2024 | 8.14 | 0.15 | 1.88% | 7.99 | 8.20 | 7.93 |
| Oct 23, 2024 | 8.02 | 0.14 | 1.78% | 7.88 | 8.08 | 7.83 |
| Oct 22, 2024 | 7.92 | 0.50 | 6.74% | 7.42 | 8.13 | 7.42 |
| Oct 21, 2024 | 7.49 | -0.05 | -0.66% | 7.54 | 7.62 | 7.42 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 2:1
- 3:1
- 5:1
- 10:1
- 20:1
- 20
- 100
- 500
- 1000
- 10000
BioCryst Company profile
BioCryst (BCRX) is a commercial-stage biotech firm that discovers novel, oral, small-molecule medicines.
The company focuses on oral treatments for rare diseases in which significant unmet medical needs exist. BioCryst’s drug portfolio consists of ORLADEYO for prevention of hereditary angioedema. ORLADEYO has been approved in the US, EU, UK, Japan and UAE. Other drugs like RAPIACTA, RAPIVAB and PERAMIFLU are approved in select geographies.
The company is developing an oral small molecule Factor D inhibitor to treat patients with paroxysmal nocturnal hemoglobinuria and other complement-mediated diseases.
According to the company, its focus on rare diseases market helps it control costs effectively. BioCryst selects disease targets and product candidates in which a small molecule would offer a significant benefit over existing products or would be the first to market.
BioCryst’s US headquarters is located in Durham, North Carolina while its European headquarters is in Dublin, Ireland. Jon P Stonehouse is the chief executive officer and William P Sheridan is the chief medical officer of BioCryst.
The company was founded in 1966. It completed its initial public offering (IPO) in March 1994 and is listed on the Nasdaq stock exchange under the ticker symbol BCRX. According to the company’s price history, BCRX stock price hit an all-time high of $37.25 on 1 March 2000.
You can follow the ups and downs of the BioCryst stock price at Capital.com. Always stay on top of the latest price developments with our live BCRX stock chart.
| Industry: | Bio Therapeutic Drugs |
4505 Emperor Blvd Ste 200
DURHAM
NORTH CAROLINA 27703-8457
US
News
Shiba Inu coin price prediction 2030: could Shiba Inu coin reach $1? Third party price target
Can Shiba Inu reinvent itself to become a worthy long-term investment?
08:36, 15 November 2024
Trump trades charge as Bitcoin hits $US80,000
Bitcoin hits $80,000 amid expectations of fiscal stimulus, lower regulatory risks, and resilient US economy.
10:48, 13 November 2024
Australian jobs data expected to point to solid labour market conditions
Australian labour market and wage data to reveal job growth resilience, shaping RBA rate cut expectations and impacting AUD amidst global economic shifts.
10:16, 13 November 2024
FOMC cuts interest rates as expected and sticks to its line on future policy
The FOMC cut interest rates by 25 basis points at its November meeting, aligning with expectations. Wall Street hit record highs following the decision, with tech stocks leading the rally. Markets are pricing in a probable December cut amid resilient economic indicators.
13:33, 8 November 2024
FOMC and BOE preview: further rate cuts expected
Both the Federal Reserve and the Bank of England are expected to cut rates further when they meet later this week.
14:14, 5 November 2024
RBA meeting preview: No change to policy expected as inflation fight continues
The Reserve Bank of Australia is expected to keep its cash rate on hold at 4.35% when it announces its policy decision at 2.30PM on the 5th of November, 2024. Despite ongoing evidence of soft demand, upside risks to inflation are likely to remain the central bank’s primary concern.
13:35, 4 November 2024
US elections: Trump leads the polls, but tariff talk spooks investors
As the US elections get closer we look at how Trump’s tariff plans could affect markets.
15:02, 22 October 2024People also watch
Still looking for a broker you can trust?
Join the 660,000+ traders worldwide that chose to trade with Capital.com